In the BioHarmony Drug Report Database
Histrelin
Supprelin, Supprelin La, Vantas (histrelin) is a protein pharmaceutical. Histrelin was first approved as Supprelin on 1991-12-24. It is used to treat precocious puberty in the USA. It is known to target gonadotropin-releasing hormone receptor. Vantas’s patent is valid until 2026-06-16 (FDA).
Trade Name
|
Supprelin, Supprelin La, Vantas |
|---|---|
Common Name
|
histrelin |
ChEMBL ID
|
CHEMBL1201255 |
Indication
|
precocious puberty |
Drug Class
|
Prehormones or hormone-release stimulating peptides |
Image (chem structure or protein)